AstraZeneca (GB:AZN) has released an update.
AstraZeneca’s Phase III CAPItello-290 trial for Truqap, aimed at treating advanced triple-negative breast cancer (TNBC), failed to meet its primary endpoints in overall survival and in patients with specific genetic alterations. Despite the setback, the company remains dedicated to understanding and treating this aggressive cancer subtype. The trial’s findings are expected to contribute to the ongoing development of the Truqap clinical program and other treatments in AstraZeneca’s oncology pipeline.
For further insights into GB:AZN stock, check out TipRanks’ Stock Analysis page.
